Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study-Reference-Cited by-同舟云学术

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study

Author:

Zane Lee T.¹,Kircik Leon²,Call Robert³,Tschen Eduardo⁴,Draelos Zoe Diana⁵,Chanda Sanjay¹,Van Syoc Merrie¹,Hebert Adelaide A.⁶

Affiliation:

1. Anacor Pharmaceuticals Palo Alto California

2. DermResearch Louisville Kentucky

3. St. Louis University St Louis Missouri

4. Academic Dermatology Associates Albuquerque New Mexico

5. Dermatology Consulting Services High Point North Carolina

6. University of Texas Health Science Center Houston Texas

Funder

Anacor Pharmaceuticals, Palo Alto, California

Publisher

Wiley

Subject

Dermatology,Pediatrics, Perinatology and Child Health

Link

Reference16 articles.

5. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases;Dastidar SG;Curr Opin Investig Drugs,2007

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. Atopik Dermatit Güncel Patofizyolojisi;Journal of Anatolian Medical Research;2024-04-15